AUPH FY2026 EPS Estimate Increased by Cantor Fitzgerald

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) – Research analysts at Cantor Fitzgerald raised their FY2026 earnings per share (EPS) estimates for shares of Aurinia Pharmaceuticals in a research report issued on Wednesday, November 5th. Cantor Fitzgerald analyst O. Brayer now forecasts that the biotechnology company will post earnings of $0.99 per share for the year, up from their previous forecast of $0.74. The consensus estimate for Aurinia Pharmaceuticals’ current full-year earnings is $0.11 per share.

Several other analysts have also issued reports on AUPH. Jefferies Financial Group raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price target for the stock from $10.00 to $21.00 in a research report on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $15.00 target price (up from $9.00) on shares of Aurinia Pharmaceuticals in a research note on Wednesday. Bloom Burton downgraded Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research report on Wednesday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $17.67.

Aurinia Pharmaceuticals Trading Up 4.7%

Shares of NASDAQ:AUPH opened at $14.61 on Friday. The company’s 50-day moving average price is $12.28 and its two-hundred day moving average price is $10.17. Aurinia Pharmaceuticals has a one year low of $6.55 and a one year high of $16.20. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63. The stock has a market capitalization of $1.92 billion, a PE ratio of 33.98 and a beta of 1.30.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.16 by $0.07. The firm had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $67.70 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Trading of Aurinia Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC increased its position in shares of Aurinia Pharmaceuticals by 56.1% in the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 1,744 shares during the period. MAI Capital Management acquired a new stake in Aurinia Pharmaceuticals during the first quarter worth about $39,000. DekaBank Deutsche Girozentrale acquired a new stake in Aurinia Pharmaceuticals during the first quarter worth about $60,000. Xponance Inc. bought a new position in Aurinia Pharmaceuticals in the 1st quarter valued at about $82,000. Finally, Kazazian Asset Management LLC acquired a new position in shares of Aurinia Pharmaceuticals in the 1st quarter valued at approximately $84,000. 36.83% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.